Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Objective: The aim of this study was to evaluate under target rates of low-density lipoproteincholesterol (LDL-C) in Korean patients with stable coronary artery disease (CAD) or an acute coronary syndrome (ACS) in real world practice. Methods: Dyslipidemia International Study II was an international observational study of patients with stable CAD or an ACS. Lipid profiles and use of lipid-lowering therapy (LLT) were documented at enrollment, and for the ACS cohort, 4 months follow-up was recommended. Rates of under target LDL-C as per European guidelines, were evaluated, and multivariate regression was performed to identify predictive factors of patients presenting under the target. Results: A total of 808 patients were enrolled in Korea, 500 with stable CAD and 308 with ACS. Of these, 90.6% and 52.6% were being treated with LLT, respectively. In the stable CAD group, 40.0% were under target LDL-C, while in ACS group, the rate was 23.7%. A higher statin dose was independently associated with under target LDL-C in both groups (OR, 1.03; p=0.046 [stable CAD] and OR, 1.05; p=0.01 [ACS]). The mean statin dosage (atorvastatin equivalent) was 17 mg/day. In the 79 ACS patients who underwent the follow-up examination, the LDL-C under target rate rose to 59.5%. Conclusion: Only a minority of patients with stable CAD or ACS were under their target LDL-C level at enrollment. The statin dose was not sufficient in the majority of patients. These results indicate a considerable LLT gap in Korean patients with established CAD.
Abstract
Objective: The aim of this study was to evaluate under target rates of low-density lipoproteincholesterol (LDL-C) in Korean patients with stable coronary artery disease (CAD) or an acute coronary syndrome (ACS) in real world practice. Methods: Dyslipidemia International Study II was an international observational study of patients with stable CAD or an ACS. Lipid profiles and use of lipid-lowering therapy (LLT) were documented at enrollment, and for the ACS cohort, 4 months follow-up was recommended. Rates of under target LDL-C as per European guidelines, were evaluated, and multivariate regression was performed to identify predictive factors of patients presenting under the target. Results: A total of 808 patients were enrolled in Korea, 500 with stable CAD and 308 with ACS. Of these, 90.6% and 52.6% were being treated with LLT, respectively. In the stable CAD group, 40.0% were under target LDL-C, while in ACS group, the rate was 23.7%. A higher statin dose was independently associated with under target LDL-C in both groups (OR, 1.03; p=0.046 [stable CAD] and OR, 1.05; p=0.01 [ACS]). The mean statin dosage (atorvastatin equivalent) was 17 mg/day. In the 79 ACS patients who underwent the follow-up examination, the LDL-C under target rate rose to 59.5%. Conclusion: Only a minority of patients with stable CAD or ACS were under their target LDL-C level at enrollment. The statin dose was not sufficient in the majority of patients. These results indicate a considerable LLT gap in Korean patients with established CAD.
참고문헌 (21)
- Baigent C, "Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins", Lancet, 366, pp.1267~1278 (2005)
- Catapano AL, "2016 ESC", EAS guidelines for the management of dyslipidaemias, 2016, pp.37, 2999~3058
- Waters DD, "Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals", Circulation, 120, pp.28~34 (2009)
- Gitt AK, "Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada", Eur J Prev Cardiol, 19, pp.221~230 (2012)
- Sung J, "Lipid-lowering treatment practice patterns in Korea: comparison with the data obtained from the CEPHEUS Pan-Asian study", J Atheroscler Thromb, 21, pp.1219~1227 (2014)
- Chiang CE, "Suboptimal control of lipid levels: results from 29 countries participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS)", J Atheroscler Thromb, 23, pp.567~587 (2016)
- American Diabetes Association, "Standards of medical care in diabetes--2013", Diabetes Care, 36(Suppl 1), pp.S11~S66 (2013)
- Chobanian AV, "The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report", JAMA, 289, pp.2560~2572 (2003)
- Mancia G, "2013 ESH", ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), 2013, pp.34, 2159~2219
- Gitt AK, "Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II", Atherosclerosis, 266, pp.158~166 (2017)
- Poh KK, "Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II", Eur J Prev Cardiol, 25, pp.1950~1963 (2018)
- Levin A, "Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease", Kidney Int Suppl, 3, pp.1~150 (2013)
- Reiner Z, "ESC", EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), 2011, pp.32, 1769~1818
- Weng TC, "A systematic review and meta-analysis on the therapeutic equivalence of statins", J Clin Pharm Ther, 35, pp.139~151 (2010)
- Lee JA, "Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care", Curr Med Res Opin, 29, pp.751~760 (2013)
- 황윤우, "Low Density Lipoprotein Cholesterol Target Goal Attainment Rate and Physician Perceptions about Target Goal Achievement in Korean Patients with Diabetes", Diabetes and Metabolism Journal, 35(6), pp.628~636 (2011), 대한당뇨병학회
- Yu SH, "Increasing achievement of the target goals for glycemic, blood pressure and lipid control for adults with diagnosed diabetes in Korea", J Diabetes Investig, 4, pp.460~465 (2013)
- Kim HS, "Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study", Curr Med Res Opin, 24, pp.1951~1963 (2008)
- Ho LT, "Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan", PLoS One, 10, pp.e0116513~ (2015)
- Park JE, "Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey", Eur J Prev Cardiol, 19, pp.781~794 (2012)
- Pearson TA, "The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals", Arch Intern Med, 160, pp.459~467 (2000)